The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Apology if seen but interesting article
From those working with Synairgen
https://www.transcrip-partners.com/news/transcrip-delighted-announce-one-trials-they-have-been-involved-running-covid-19-has-generated
Vlad does like to drop tweets but for me he has never followed it up with positive news, its the research that they are doing that keeps me invested here and Car T-Cells play an important role with or without Covid and they have a stellar team.
In for the long haul here or if extremely lucky, when he drops the all mother of RNS News.......In Vlad we Trust (unlike Trump the fool)
Positive news but as this virus mutates, will it cover all mutations? hope so as the world needs to fight this pandemic with all medical solutions.
No idea if meant for this board
I did read an article yesterday that he had tweeted about which mentioned how T-Cells could be used to help with Covid, his field of expertise and as per RNS below, it must be due. Along with everyone else reporting on Covid finds.
Meanwhile, as announced on 22 April 2020, the Company has progressed its work, currently using blood samples from convalescent patients, to attempt to establish why some individuals who are infected with SARS-CoV-2 are asymptomatic, some exhibit mild symptoms, and some become very sick. This work will be of value in developing new forms of treatment, and especially in managing infection risk and assisting individuals better to establish their real risk of getting sick.
I hope one of those days where News Lands and the dip is a distant memory when it shoots up and Hemo becomes a huge player.
Ok maybe a little too positive and its just a lull in the proceedings.
Its been a while since an RNS and it is month end, so maybe something will drop
It would appear to be, anything could happen at any time. The Lilly announcement dropped out of the blue and Vlad doesn't mind a 3pm'ish RNS. Be nice to have something today for an exciting finish to the week.
This needs to be shared as surely an RNS due
Great news that the
@GOVUK
has agreed, subject to final contract, to purchase 60m doses of the #COVID19 vaccine candidate we’re co-developing with Sanofi combining our pandemic adjuvant system with
@Sanofi’s recombinant protein technology.
A SOUTHAMPTON-led trial that could protect against Covid-19 could help patients recover if a second wave hits.
It comes after it was revealed that an inhaled drug helped some patients fully recover from coronavirus.
Drug development company Synairgen announced that positive results were found from a trial, which involved hospitalised coronavirus patients inhaling a drug called interferon beta, otherwise known as SNG001.
Led by University of Southampton and Synairgen, patients who received SNG001 had a 79 per cent lower risk of developing a severe disease compared to a placebo.
Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and Trial Chief Investigator, said: “Twice as many in the study made a full recovery and it seems to speed up the rate that people recover.
“We are talking to organisations around the world to see how to deliver the next trial as rapidly as possible.
“If there are concerns for a second wave this winter, we will hopefully be at the next stage of development by then.
“The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus.”
Both researchers and the 101 patients did not know whether they were receiving SNG001 or a placebo.
Patients receiving SNG001 were more than twice as likely to recover from Covid-19 as those on the placebo drug.
Southampton Itchen MP Royston Smith said: “This is very good news indeed.Early signs are that this new drug is very positive and could well be a successful treatment to beat Covid-19.”
While MP for Southampton Test Alan Whitehead said: “The initial results certainly look promising and it’s great that Southampton is playing it’s part in developing new drugs to help fight Covid-19.”
We are forgetting that Covid is evolving and one vaccine will work for some but not for others, so treatment has a huge part to play as we have many different strains of Covid and the WHO yesterday said its not a wave 2 but just one huge Wave.
Let alone this Virus seems to like all weathers regardless
This board has been quiet for sometime, since the webinar where Vlad scared a lot of people and it spiked and dropped.
SP just ticks up and down between 7 & 8, which isnt bad considering it did drop below placing price for a while. Im sure the team at HEMO are working hard and with America having real issues, working even harder.
The covid play that was in one of the RNS must be due an update, as many other pharma's and presenting initial views. Maybe news is brewing and about to drop to help out Trump and the Globe.
Sales for injected version are extreme
In the United States as of 2015 the cost is between US$1,284 and US$1,386 per 30 mcg vial.[26] As of 2020, the National Average Drug Acquisition Cost (NADAC) in the United States for Avonex was $6,872.94 for a 30 mcg kit. [27]
Avonex and Rebif are under the top 10 best-selling multiple sclerosis drugs of 2013:[28]
Having done some research into HEMO and the opportunity for them to flourish, I agree it looks like minimal risk but I guess with any share you have to consider losing the investment, but not until you sell.
Id like to hold 2m shares but certainly not got the surplus to invest and happy with my 100k and patiently waiting for the flurry of positive news.
Goodluck All